The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

ASH 2018 | Phase I study of HCG/EGF adjunct therapy in high-risk and steroid refractory acute graft-versus-host disease

Dec 17, 2018

On Saturday 1 December 2018, an oral abstract session took place at the  60 th American Society of Hematology (ASH) Annual Meeting in San Diego, CA. During Session: 722. Clinical Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: GVHD Grading and Outcomes and Management, Abstract #71was presented by Shernan G. Holtan, University of Minnesota, Minneapolis, MN, USA, entitled:  Facilitating Resolution of Life-Threatening Acute Graft-Versus-Host Disease By Supplementation of Human Chorionic Gonadotropin (hCG) and Epidermal Growth Factor (EGF) (Pregnyl): A Phase I Study.

This phase I study was conducted to evaluate hCG/EGF in patients with Minnesota High Risk and steroid dependent or refractory acute graft-versus-host disease (aGvHD) to improve both hCG-mediated immunologic tolerance and tissue repair via supplemental EGF. Urinary-derived hCG (Pregnyl®) was given to patients with aGvHD in addition to standard of care.

Patients and methods

N = 26 patients

  • Arm 1: N = 13 patients (median age = 65 years) were high-risk and received first line Pregnyl® SQ QOD for 7 days
  • Arm 2: N = 13 patients (median age = 65 years) were steroid refractory and received Pregnyl® as second line treatment SQ QOD for 14 days

Key findings

  • hCG/EGF was well tolerated, with no dose-limiting toxicities
  • Median EGF dose: 50,833 pg/ml
  • Most common treatment emergent adverse event was edema in 16 patients (62%)
  • Proportion of day-28 response
    • Arm 1:
      • CR: 62%
      • PR: 0
      • NR: 38%
    • Arm 2:
      • CR: 54%
      • PR: 8%
      • NR: 38%
    • Pregnyl® does not worsen cytopenias
    • Pregnyl® increases serum hCG, estradiol, and testosterone; all returned to baseline by day 56
    • Pregnyl® may support Treg/Tcon ratio
    • AREG significantly decreases over time in patients with day-28 CR/PR

In conclusion, Pregnyl® appears “safe and feasible supportive care in first and second line severe aGvHD.” Pregnyl® may facilitate tolerance and tissue repair, without adding to side-effects of GvHD treatment. Doctor Holtan added that “the optimal dose and duration of hCG/EGF are under investigation, with ongoing dose escalation in patients with steroid-refractory aGvHD based upon these initial results.”

  1. Holtan S.G. et al. Facilitating resolution of life-threatening acute graft-versus-host disease by supplementation of human chorionic gonadotropin and epidermal growth factor (Pregnyl): A Phase I study. 2018 Dec 1. Abstract #71. ASH 60th Annual Meeting and Exposition, San Diego, CA.